Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol

Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.

Ahmedabad, 24^th May 2022:  Ahmedabad-based Cadila Pharmaceuticals has launched a novel drug for the treatment of high LDL cholesterol for the first time in India.

To be sold under the brand name Belmore, Bempedoic acid is a one-of-its-kind drug for the treatment of high LDL (low-density lipoprotein) cholesterol, also known as bad cholesterol.

High LDL cholesterol can lead to serious life-threatening heart complications due to blockage in blood vessels.

As per published data, more than 30 % of adults in urban areas and 20 % in rural areas in India are suffering from this silent disease. Statins are the group of drugs used to control LDL cholesterol but in more than 80 % of the patients, these drugs either do not give optimum control or are not tolerated.

“Belmore (bempedoic acid) provides additional benefits to patients, and all pre-launch studies have established this advantage. Belmore is one more addition to our fast-growing portfolio of indigenous innovations. We are committed to continuing our journey of making affordable drugs available to everyone,” said Jawad Zia, CEO, Domestic  Prescription Business, Cadila Pharmaceuticals Ltd.

Cadila Pharmaceuticals is one of the largest privately-held pharma companies in the country and has been engaged in the development and production of high-quality but affordable medicines for patients around the world. The launch of Belmore, which helps in lowering LDL-cholesterol level and lowers the risk of heart ailments, is another important milestone in the fight against cardiovascular diseases.